Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R B LivingstonC A Long

Abstract

We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received elective growth factor support with granulocyte colony-stimulating factor (G-CSF; filgrastim) in an attempt to maximize delivered dose-intensity (DDI). Objective tumor response, DDI, and toxicity were assessed, as well as time to progression (TTP) and survival. This single-center nonrandomized trial enrolled 40 patients. Anthracycline exposure and subsequent progression were common to all patients, and 38 of 40 were paclitaxel-refractory. Vinorelbine was given initially at 30 mg/m2/wk, then at 35 mg/m2/wk in a phase I/II design, which involved first intermittent (6 days of 7) and then continuous (daily) administration of G-CSF at 5 micrograms/kg. The maximum-tolerated starting dose was 35 mg/m2/wk with continuous G-CSF support. The mean DDI was 27.7 mg/m2/wk for all patients. There were two complete responses (CRs) and eight partial responses (PRs) in 40 assessable patients for an overall response rate of 25% (95% confidence interval [CI], 13% to 41%). The median TTP was 13 weeks and median survival time 33 weeks. The dose-limiting toxicity was neutropenia, with dose delay or...Continue Reading

Citations

Apr 13, 1999·American Journal of Clinical Oncology·A J WeissR D Lackmen
Dec 7, 2000·Cancer Investigation·D R BudmanW Kreis
Apr 18, 2001·The Oncologist·F J EstevaG N Hortobagyi
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George P StathopoulosJohn G Stathopoulos
Nov 27, 2004·Breast Cancer Research and Treatment·J Y PiergaUNKNOWN Cooperative Group of the French capecitabine compassionate use program
Apr 15, 2006·Expert Review of Anticancer Therapy·Ruth E BoardAndrew M Wardley
Jun 7, 2007·British Journal of Cancer·N AlamiB Leyland-Jones
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L BlumT Griffin
Mar 31, 2010·Magyar onkologia·Nagykálnai TamásMészáros Edina
Jun 30, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·John S Ng
Nov 1, 2002·Breast Cancer Research and Treatment·Javier RodríguezOscar Fernández-Hidalgo
May 23, 2002·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Jun KinoshitaTetsuro Kajiwara
Apr 7, 2007·American Journal of Clinical Oncology·Louis Wing-Cheong ChowBrian Hung-Hin Lang
Apr 8, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Linda T VahdatJoanne L Blum
Jul 16, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Joyce O'Shaughnessy
May 19, 2011·Annals of Medicine·Ricardo H AlvarezGabriel N Hortobagyi
Dec 20, 2013·Breast Cancer Research and Treatment·Julie R GralowGabriel N Hortobagyi
Jun 13, 2002·Breast Cancer Research and Treatment·Javier Abel MenéndezRamon Colomer
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezShaker R Dakhil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
B L WeberJ Hohneker
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D W MilesP G Harper
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G V KornekW Scheithauer
© 2021 Meta ULC. All rights reserved